Patents Assigned to Beijing Mabworks Biotech Co. Ltd.
-
Patent number: 11970541Abstract: The present invention relates to a humanized anti-CD20 antibody that comprises an antigen binding site containing heavy and light chain of obinutuzumab (GAZYVA®), and N-linked oligosaccharides that are attached to the Fc region of the antibody, wherein the N-linked oligosaccharides are not bisected by N-acetylglucosamine. The antibody of the present invention comprises fucose glycotype in an amount of no more than 10% of the total N-glycans that are attached to the Fc region of the antibody. The anti-CD20 of the present invention has antibody dependent cell-mediated cytotoxicity (ADCC) about 2 times stronger than that of GAZYVA® and about 50 to 100 times stronger than that of RITUXAN®. The anti-CD20 antibodies are effective for treating CD20 expressing cancer, such as non-Hodgkin's lymphoma, B cell lymphoma, chronic lymphocytic leukemia, or follicular lymphoma.Type: GrantFiled: November 19, 2021Date of Patent: April 30, 2024Assignee: BEIJING MABWORKS BIOTECH CO. LTD.Inventors: Feng Li, Boyan Zhang, Pei Ye
-
Patent number: 11718674Abstract: An isolated monoclonal antibody, or an antigen-binding portion thereof, that specifically binds human PD0-L1. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immuneconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the antibody or antigen-binding portion thereof.Type: GrantFiled: August 30, 2021Date of Patent: August 8, 2023Assignee: BEIJING MABWORKS BIOTECH CO., LTD.Inventors: Jiangmei Li, Wenqi Hu, Feng Li
-
Patent number: 11208492Abstract: The present invention relates to a humanized anti-CD20 antibody that comprises an antigen binding site containing heavy and light chain of obinutuzumab (GAZYVA®), and N-linked oligosaccharides that are attached to the Fc region of the antibody, wherein the N-linked oligosaccharides are not bisected by N-acetylglucosamine. The antibody of the present invention comprises fucose glycotype in an amount of no more than 10% of the total N-glycans that are attached to the Fc region of the antibody. The anti-CD20 of the present invention has antibody dependent cell-mediated cytotoxicity (ADCC) about 2 times stronger than that of GAZYVA® and about 50 to 100 times stronger than that of RITUXAN®. The anti-CD20 antibodies are effective for treating CD20 expressing cancer, such as non-Hodgkin's lymphoma, B cell lymphoma, chronic lymphocytic leukemia, or follicular lymphoma.Type: GrantFiled: February 13, 2019Date of Patent: December 28, 2021Assignee: BEIJING MABWORKS BIOTECH CO. LTD.Inventors: Feng Li, Boyan Zhang, Pei Ye
-
Patent number: 11091558Abstract: An isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human OX40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-OX40 antibody of the invention.Type: GrantFiled: October 14, 2019Date of Patent: August 17, 2021Assignee: BEIJING MABWORKS BIOTECH CO. LTD.Inventors: Wenqi Hu, Jiangmei Li, Lun Jiang, Feng Li
-
Patent number: 10946092Abstract: An isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human LAG3. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immuneconjugate, a bispecific molecule, a chimeric antigen receptor, and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof thereof, as well as a treatment method using the same.Type: GrantFiled: August 3, 2020Date of Patent: March 16, 2021Assignees: BEIJING MABWORKS BIOTECH CO., LTD., BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.Inventors: Wenqi Hu, Jiangmei Li, Feng Li
-
Patent number: 10662249Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.Type: GrantFiled: December 23, 2019Date of Patent: May 26, 2020Assignees: BEIJING MABWORKS BIOTECH CO., LTD., BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.Inventors: Wenqi Hu, Jiangmei Li, Feng Li
-
Patent number: 10654937Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.Type: GrantFiled: December 23, 2019Date of Patent: May 19, 2020Assignees: BEIJING MABWORKS BIOTECH CO., LTD., BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.Inventors: Wenqi Hu, Jiangmei Li, Feng Li
-
Patent number: 10654938Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.Type: GrantFiled: December 23, 2019Date of Patent: May 19, 2020Assignees: BEIJING MABWORKS BIOTECH CO., LTD., BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.Inventors: Wenqi Hu, Jiangmei Li, Feng Li
-
Patent number: 10654939Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.Type: GrantFiled: December 23, 2019Date of Patent: May 19, 2020Assignees: BEIJING MABWORKS BIOTECH CO., LTD., BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.Inventors: Wenqi Hu, Jiangmei Li, Feng Li
-
Patent number: 10647776Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.Type: GrantFiled: December 23, 2019Date of Patent: May 12, 2020Assignees: BEIJING MABWORKS BIOTECH CO., LTD., BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.Inventors: Wenqi Hu, Jiangmei Li, Feng Li
-
Patent number: 10577424Abstract: An isolated monoclonal antibody or the antigen binding portion thereof that specifically binds human VISTA. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody or the antigen binding portion thereof are also provided. The present disclosure further provides a bispecific molecule, and a pharmaceutical composition comprising the antibody or the binding moieties thereof, as well as a treatment method using an anti-VISTA antibody or the antigen binding portion thereof of the present disclosure.Type: GrantFiled: August 15, 2019Date of Patent: March 3, 2020Assignee: Beijing Mabworks Biotech Co., Ltd.Inventors: Wenqi Hu, Jiangmei Li, Feng Li
-
Patent number: 10570210Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.Type: GrantFiled: March 4, 2019Date of Patent: February 25, 2020Assignee: Beijing Mabworks Biotech Co.LtdInventors: Wenqi Hu, Jiangmei Li, Feng Li
-
Patent number: 10442866Abstract: An isolated monoclonal antibody that specifically binds human OX40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-OX40 antibody of the invention.Type: GrantFiled: January 23, 2019Date of Patent: October 15, 2019Assignee: Beijing Mabworks Biotech Co. LtdInventors: Wenqi Hu, Jiangmei Li, Lun Jiang, Feng Li
-
Patent number: 10421817Abstract: An isolated monoclonal antibody that specifically binds human Claudin 18.2. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a diagnostic or treatment method using an anti-Claudin 18.2 antibody of the invention.Type: GrantFiled: January 22, 2019Date of Patent: September 24, 2019Assignee: BEIJING MABWORKS BIOTECH CO., LTD.Inventors: Wenqi Hu, Jiangmei Li, Xia Wang, Feng Li
-
Patent number: 10377833Abstract: The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies. The present invention also relates to Chinese Hamster ovary (CHO) mutant cell line that has a dysfunctional Slc35C1 gene, which is the only dysfunctional gene in the mutant that affects glycan regulation.Type: GrantFiled: July 21, 2017Date of Patent: August 13, 2019Assignee: Beijing Mabworks Biotech Co., Ltd.Inventors: Feng Li, Boyan Zhang, Pei Ye, Jian Zhao, Sijia Huang, Chunyang Jin
-
Patent number: 9745382Abstract: The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies.Type: GrantFiled: March 17, 2017Date of Patent: August 29, 2017Assignee: Beijing Mabworks Biotech Co. Ltd.Inventors: Feng Li, Boyan Zhang, Pei Ye, Jian Zhao, Sijia Huang, Chunyang Jin